Medrol 16 mg

Uses of Medrol: - Rheumatic disorder - Skin disorders - Eye disorders - Nephrotic syndrome - Systemic lupus erythematosus (SLE) Anti-inflammatory or immunosuppressive, Allergic conditions Systemic fungal infections and known hypersensitivity to components.

How to use Methylprednisolone: Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Methylprednisolone is to be taken with food. Avoid Methylprednisolone with dietary sodium. Administration: Should be taken with food. Adult Dose: Oral Anti-inflammatory or immunosuppressive Adult: Initially, 2-60 mg daily in 1-4 divided doses, depending on the disease being treated. Allergic conditions Adult: 24 mg on day 1 (8 mg before breakfast, 4 mg after lunch, 4 mg after supper, and 8 mg at bedtime) or 24 mg as a single or in 2-3 divided doses upon initiation (regardless of time of day); 20 mg on day 2 (4 mg before breakfast, 4 mg after lunch, 4 mg after supper, and 8 mg at bedtime); 16 mg on day 3 (4 mg before breakfast, 4 mg after lunch, 4 mg after supper, and 4 mg at bedtime); 12 mg on day 4 (4 mg before breakfast, 4 mg after lunch, and 4 mg at bedtime); 8 mg on day 5 (4 mg before breakfast and 4 mg at bedtime); 4 mg on day 6, given before breakfast. May be tapered over 12 days (to decrease chance of dermatitis flareup) Child Dose: Oral Anti-inflammatory or immunosuppressive Child: 0.5-1.7 mg/kg daily or 5-25 mg/m2 daily in divided doses 6-12 hrly. Usual dosing range, 0.117-1.66 mg/kg/day PO divided q6-8hr

Loss of corticosteroid-induced adrenal suppression w/ aminoglutethimide. Risk of hypokalaemia w/ K-depleting agents (e.g. amphotericin B, diuretics). Decreased clearance w/ macrolide antibiotics. May decrease serum levels of isoniazid. Increased clearance w/ cholestyramine. Risk of convulsions w/ ciclosporin. Increased risk of arrhythmias w/ digitalis glycosides. Decreased metabolism w/ oestrogens, including OCs. Enhanced metabolism w/ CYP3A4 inducers (e.g. rifampicin, barbiturates). Increased plasma concentrations w/ CYP3A4 inhibitors (e.g. ketoconazole, erythromycin). Risk of GI effects w/ aspirin or other NSAIDs. May increase the anticoagulant effect of warfarin. May reduce the therapeutic effect of antidiabetics. Potentially Fatal: May diminish response to live or live, attenuated vaccines.

Systemic fungal infections and known hypersensitivity to components.

Common - Thinning of skin - Increased risk of infection - Reduction in bone density - Weight gain - Mood changes - Upset stomach - Behavioural changes Adrenal suppression, anaphylactoid reactions, immunosuppression, acute myopathy, Kaposi's sarcoma, psychiatric disturbances (e.g. depression, euphoria, insomnia, mood swings, personality changes), increased susceptibility and severity of infections, impaired healing, HTN, Na and fluid retention, CV collapse (high dose), peptic ulcer, cataract subcapsular, skin atrophy, acne, muscular weakness, growth retardation, decreased blood K; dermal/subdermal skin depression at inj site. Topical: Itching, burning erythema, vesiculation; rarely, folliculitis, hypertrichosis, perioral dermatitis, skin discolouration, allergic skin reactions.

Precaution: Patient w/ heart failure, HTN, DM, GI disease (e.g. diverticulitis, intestinal anastomoses, peptic ulcer, ulcerative colitis), multiple sclerosis, myasthenia gravis, acute MI, cataracts, glaucoma, osteoporosis, history of seizure disorder, thyroid disease. Avoid abrupt withdrawal. Renal and hepatic impairment (including cirrhosis). Childn. Pregnancy and lactation. Monitoring Parameters Monitor BP, blood glucose, electrolytes, growth in childn. Lactation: Drug enters milk; use with caution

Report of acute toxicity and/or death following an overdose of glucocorticoid ere rare. No specific antidote is available; treatment is supportive and symptomatic. Serum electrolytes should be monitored.

Store in a cool and dry place, away from light. Keep out of reach of children.

Glucocorticoids

Methylprednisolone is a synthetic corticosteroid with mainly glucocorticoid activity and minimal mineralocorticoid properties. It decreases inflammation by suppression of migration of polymorphonuclear leukocytes and reversal of increased capillary permeability.

Pregnancy category C. Dregs should be given only if the potential benefit justifies the potential risk te the foetus. Mefhyiprednisofone has not been adequately evaluated in nursing mothers.